WuXi Biologics (Cayman) Inc (2269.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN KYG970081173
WuXi Biologics (Cayman) Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 18.68 bn CNY | 21.79 bn CNY |
| Gross profit | 7.65 bn CNY | 11.66 bn CNY |
| EBIT | 4.97 bn CNY | 7.73 bn CNY |
| Net income | 3.36 bn CNY | 4.91 bn CNY |
| Diluted EPS – continuing operations | 0.79 CNY | 1.37 CNY |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About WuXi Biologics (Cayman) Inc
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Tumor Associated Antigens (TAA) mAb Technology, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; research and development in relation to biologics; international sales contracting service; vaccine contract development and manufacturing organization (CDMO) and related business; development, production, and distribution of biotechnological products; and engages in investment and material supplier activities. WuXi Biologics (Cayman) Inc. was incorporated in 2014 and is headquartered in Wuxi, China.
More stocks
- West Pharmaceutical Services (WST)
- Tencent Music Entertainment Group (TME)
- Citizens Financial Group (CFG)
- LARGAN Precision Co Ltd (3008.TW)
- Otis Worldwide (OTIS)
- Inner Mongolia Yili Industrial Group Co Ltd (600887.SS)
- SJ Semiconductor Corp (688820.SS)
- FirstEnergy (FE)
- Nan Ya Printed Circuit Board Corp (8046.TW)
- Avary Holding Shenzhen Co Ltd Class A (002938.SZ)
- Amadeus IT Group SA (AMS.MC)
- Dover Corporation (DOV)
Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.